Skip to main content
Top
Published in: Endocrine 1/2013

01-02-2013 | Original Article

Coronary microvascular function in patients with Cushing’s syndrome

Authors: Francesco Fallo, Giulia Famoso, Dario Capizzi, Nicoletta Sonino, Francesca Dassie, Pietro Maffei, Chiara Martini, Agostino Paoletta, Sabino Iliceto, Francesco Tona

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

The aim of the study was to evaluate patients with Cushing’s syndrome the coronary flow reserve (CFR), an index of coronary microvascular function. Fifteen newly diagnosed patients with Cushing’s syndrome (1 male/14 females; mean age 45 ± 11 years), were selected for having no clinical evidence of ischemic heart disease. Twelve patients had pituitary-dependent Cushing’s disease and three had an adrenal adenoma. Fifteen subjects matched for age, sex, and major cardiovascular risk factors were used as controls. Coronary flow velocity in the left anterior descending coronary artery was investigated by transthoracic Doppler echocardiography at rest and during adenosine infusion. CFR was obtained as the ratio hyperemic/resting diastolic flow velocity. A reduced coronary reserve (hyperemic/resting ratio ≤2.5) was found in 5/15 Cushing patients and 4/15 controls. In all patients with abnormal CFR, epicardial coronary stenosis was excluded by multi-slice computed tomographic coronary angiography. CFR was inversely related to urinary cortisol in patients with endogenous hypercortisolism (Spearman’s rho = −0.57, P = 0.03), while no correlation was found in controls. Coronary microvascular function, as assessed by CFR, is pathologically reduced in a considerable number of patients with Cushing’s syndrome without clinical symptoms of ischemic heart disease and in the absence of epicardial coronary artery lesions, as well as in controls matched for cardiovascular risk factors. The presence of comorbidities can explain this early coronary abnormality in both patients and controls. Whether urinary cortisol may be a predictor of coronary microvascular function in the setting of patients with Cushing’s syndrome, needs further investigation.
Literature
1.
2.
go back to reference G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMedCrossRef G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMedCrossRef
3.
go back to reference T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. (Oxf) 61, 768–777 (2004)CrossRef T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. (Oxf) 61, 768–777 (2004)CrossRef
4.
go back to reference R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and the cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34, 327–339 (2005)PubMedCrossRef R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and the cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34, 327–339 (2005)PubMedCrossRef
5.
go back to reference F. Fallo, N. Sonino, Should we evaluate for cardiovascular disease in patients with Cushing’s syndrome? Clin. Endocrinol. (Oxf) 71, 768–771 (2009)CrossRef F. Fallo, N. Sonino, Should we evaluate for cardiovascular disease in patients with Cushing’s syndrome? Clin. Endocrinol. (Oxf) 71, 768–771 (2009)CrossRef
6.
go back to reference R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96, 632–642 (2011)PubMedCrossRef R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96, 632–642 (2011)PubMedCrossRef
7.
go back to reference M.L. Muiesan, M. Lupia, M. Salvetti, C. Grigoletto, N. Sonino, M. Boscaro, E.A. Rosei, F. Mantero, F. Fallo, Left ventricular structural and functional characteristics in Cushing’s syndrome. J. Am. Coll. Cardiol. 41, 2275–2279 (2003)PubMedCrossRef M.L. Muiesan, M. Lupia, M. Salvetti, C. Grigoletto, N. Sonino, M. Boscaro, E.A. Rosei, F. Mantero, F. Fallo, Left ventricular structural and functional characteristics in Cushing’s syndrome. J. Am. Coll. Cardiol. 41, 2275–2279 (2003)PubMedCrossRef
8.
go back to reference A.M. Pereira, V. Delgado, J.A. Romijn, J.W. Smit, J.J. Bax, R.A. Feelders, Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur. J. Endocrinol. 162, 331–340 (2010)PubMedCrossRef A.M. Pereira, V. Delgado, J.A. Romijn, J.W. Smit, J.J. Bax, R.A. Feelders, Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur. J. Endocrinol. 162, 331–340 (2010)PubMedCrossRef
9.
go back to reference K.H. Yiu, N.A. Marsan, V. Delgado, N.R. Biermasz, E.R. Holman, J.W. Smit, R.A. Feelders, J.J. Bax, A.M. Pereira, Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur. J. Endocrinol. 166, 27–34 (2012)PubMedCrossRef K.H. Yiu, N.A. Marsan, V. Delgado, N.R. Biermasz, E.R. Holman, J.W. Smit, R.A. Feelders, J.J. Bax, A.M. Pereira, Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur. J. Endocrinol. 166, 27–34 (2012)PubMedCrossRef
10.
go back to reference P.M. Toja, G. Branzi, F. Ciambellotti, P. Radaelli, M. De Martin, L.M. Lonati, M. Scacchi, G. Parati, F. Cavagnini, F.P. Giraldi, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin. Endocrinol. (Oxf) 76, 332–338 (2012)CrossRef P.M. Toja, G. Branzi, F. Ciambellotti, P. Radaelli, M. De Martin, L.M. Lonati, M. Scacchi, G. Parati, F. Cavagnini, F.P. Giraldi, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin. Endocrinol. (Oxf) 76, 332–338 (2012)CrossRef
11.
go back to reference K.L. Gould, K. Lipscom, G.W. Hamilton, Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am. J. Cardiol. 33, 87–94 (1974)PubMedCrossRef K.L. Gould, K. Lipscom, G.W. Hamilton, Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am. J. Cardiol. 33, 87–94 (1974)PubMedCrossRef
12.
go back to reference C. Caiati, C. Montaldo, N. Zedda, R. Montisci, M. Ruscazio, G. Lai, M. Cadeddu, L. Meloni, S. Iliceto, Validation of a new noninvasive method (contrast enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve. Comparison with intracoronary Doppler flow wire. J. Am. Coll. Cardiol. 34, 1193–2000 (1999)PubMedCrossRef C. Caiati, C. Montaldo, N. Zedda, R. Montisci, M. Ruscazio, G. Lai, M. Cadeddu, L. Meloni, S. Iliceto, Validation of a new noninvasive method (contrast enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve. Comparison with intracoronary Doppler flow wire. J. Am. Coll. Cardiol. 34, 1193–2000 (1999)PubMedCrossRef
13.
go back to reference P.G. Camici, F. Crea, Coronary microvascular dysfunction. N. Eng. J. Med. 356, 830–840 (2007)CrossRef P.G. Camici, F. Crea, Coronary microvascular dysfunction. N. Eng. J. Med. 356, 830–840 (2007)CrossRef
14.
go back to reference T. Kiviniemi, Assessment of coronary blood flow and the reactivity of the microcirculation non-invasively with transthoracic echocardiography. Clin. Physiol. Funct. Imag. 28, 145–155 (2008)CrossRef T. Kiviniemi, Assessment of coronary blood flow and the reactivity of the microcirculation non-invasively with transthoracic echocardiography. Clin. Physiol. Funct. Imag. 28, 145–155 (2008)CrossRef
15.
go back to reference D. Rizzoni, C. Palombo, E. Porteri, M.L. Muiesan, M. Kozàkovà, G. La Canna, M. Nardi, D. Guelfi, M. Salvetti, C. Morizzo, F. Vittone, E.A. Rosei, Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J. Hypertens. 21, 625–631 (2003)PubMedCrossRef D. Rizzoni, C. Palombo, E. Porteri, M.L. Muiesan, M. Kozàkovà, G. La Canna, M. Nardi, D. Guelfi, M. Salvetti, C. Morizzo, F. Vittone, E.A. Rosei, Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J. Hypertens. 21, 625–631 (2003)PubMedCrossRef
16.
go back to reference M. Ragosta, H. Samady, R.B. Isaacs, L.W. Gimple, I.J. Sarembock, E.R. Powers, Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am. Heart J. 147, 1017–1023 (2004)PubMedCrossRef M. Ragosta, H. Samady, R.B. Isaacs, L.W. Gimple, I.J. Sarembock, E.R. Powers, Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am. Heart J. 147, 1017–1023 (2004)PubMedCrossRef
17.
go back to reference M. Galderisi, G. de Simone, S. Cicala, M. Parisi, A. D’Errico, P. Innelli, M. de Divitiis, S. Mondillo, O. de Divitiis, Coronary flow reserve in hypertensive patients with hypercholesterolemia and without coronary heart disease. Am. J. Hypertens. 20, 177–183 (2007)PubMedCrossRef M. Galderisi, G. de Simone, S. Cicala, M. Parisi, A. D’Errico, P. Innelli, M. de Divitiis, S. Mondillo, O. de Divitiis, Coronary flow reserve in hypertensive patients with hypercholesterolemia and without coronary heart disease. Am. J. Hypertens. 20, 177–183 (2007)PubMedCrossRef
18.
go back to reference F. Fallo, A. Paoletta, F. Tona, M. Boscaro, N. Sonino, Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing’s syndrome. J. Int. Med. 234, 595–598 (1993)CrossRef F. Fallo, A. Paoletta, F. Tona, M. Boscaro, N. Sonino, Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing’s syndrome. J. Int. Med. 234, 595–598 (1993)CrossRef
19.
go back to reference P. Della Mea, M. Lupia, V. Bandolin, S. Guzzon, N. Sonino, R. Vettor, F. Fallo, Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am. J. Hypertens. 18, 30–35 (2005)PubMedCrossRef P. Della Mea, M. Lupia, V. Bandolin, S. Guzzon, N. Sonino, R. Vettor, F. Fallo, Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am. J. Hypertens. 18, 30–35 (2005)PubMedCrossRef
20.
go back to reference R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H. Picard, M.J. Roman, J. Seward, J. Shanewise, S. Solomon, K.T. Spencer, M. St John Sutton, W. Stewart, American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur. J. Echocardiogr. 7, 79–108 (2006) R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H. Picard, M.J. Roman, J. Seward, J. Shanewise, S. Solomon, K.T. Spencer, M. St John Sutton, W. Stewart, American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur. J. Echocardiogr. 7, 79–108 (2006)
21.
go back to reference G. de Simone, S.R. Daniels, R.B. Devereux, R.A. Meyer, M.J. Roman, O. de Divitiis, M.H. Alderman, Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J. Am. Coll. Cardiol. 19, 1550–1558 (1992)PubMedCrossRef G. de Simone, S.R. Daniels, R.B. Devereux, R.A. Meyer, M.J. Roman, O. de Divitiis, M.H. Alderman, Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J. Am. Coll. Cardiol. 19, 1550–1558 (1992)PubMedCrossRef
22.
go back to reference F. Tona, A.L. Caforio, R. Montisci, A. Gambino, A. Angelini, M. Ruscazio, G. Toscano, G. Feltrin, A. Ramondo, G. Gerosa, S. Iliceto, Coronary flow velocity pattern and coronary flow reserve by contrast-enhanced transthoracic echocardiography predict long-term outcome in heart transplantation. Circulation 114(1 Suppl), I49–I55 (2006)PubMed F. Tona, A.L. Caforio, R. Montisci, A. Gambino, A. Angelini, M. Ruscazio, G. Toscano, G. Feltrin, A. Ramondo, G. Gerosa, S. Iliceto, Coronary flow velocity pattern and coronary flow reserve by contrast-enhanced transthoracic echocardiography predict long-term outcome in heart transplantation. Circulation 114(1 Suppl), I49–I55 (2006)PubMed
23.
go back to reference R. Rubinshtein, E.H. Yang, C.S. Rihal, A. Prasad, R.J. Lennon, P.J. Best, L.O. Lerman, A. Lerman, Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur. Heart J. 31, 936–942 (2010)PubMedCrossRef R. Rubinshtein, E.H. Yang, C.S. Rihal, A. Prasad, R.J. Lennon, P.J. Best, L.O. Lerman, A. Lerman, Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur. Heart J. 31, 936–942 (2010)PubMedCrossRef
24.
go back to reference W.G. Austen, J.E. Edwards, R.L. Frye, G.G. Gensini, V.L. Gott, L.S. Griffith, D.C. McGoon, M.L. Murphy, B.B. Roe, A reporting system on patients evaluated for coronary artery disease: report of the ad hoc committee for grading of coronary artery disease, Council on Cardiovascular Surgery, Dallas, TX: American Heart Association. Circulation 51, 5–40 (1975)PubMedCrossRef W.G. Austen, J.E. Edwards, R.L. Frye, G.G. Gensini, V.L. Gott, L.S. Griffith, D.C. McGoon, M.L. Murphy, B.B. Roe, A reporting system on patients evaluated for coronary artery disease: report of the ad hoc committee for grading of coronary artery disease, Council on Cardiovascular Surgery, Dallas, TX: American Heart Association. Circulation 51, 5–40 (1975)PubMedCrossRef
25.
go back to reference F. Rigo, L. Cortigiani, E. Pasanisi, M. Richieri, V. Cutaia, M. Celestre, A. Raviele, E. Picano, The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study. Am. Heart J. 151, 124–130 (2006)PubMedCrossRef F. Rigo, L. Cortigiani, E. Pasanisi, M. Richieri, V. Cutaia, M. Celestre, A. Raviele, E. Picano, The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study. Am. Heart J. 151, 124–130 (2006)PubMedCrossRef
26.
go back to reference G.D. Smith, Y. Ben-Shlomo, A. Beswick, J. Yarnell, S. Lightman, P. Elwood, Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112, 332–340 (2005)PubMedCrossRef G.D. Smith, Y. Ben-Shlomo, A. Beswick, J. Yarnell, S. Lightman, P. Elwood, Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112, 332–340 (2005)PubMedCrossRef
27.
go back to reference J. Nijm, L. Jonasson, Inflammation and cortisol response in coronary artery disease. Ann. Med. 41, 224–233 (2009)PubMedCrossRef J. Nijm, L. Jonasson, Inflammation and cortisol response in coronary artery disease. Ann. Med. 41, 224–233 (2009)PubMedCrossRef
28.
go back to reference R. Fraser, M.C. Ingram, N.H. Andre, C. Morrison, E. Davies, J.M.C. Connell, Cortisol effects on body mass, blood pressure and cholesterol in the general population. Hypertension 33, 1364–1368 (1999)PubMedCrossRef R. Fraser, M.C. Ingram, N.H. Andre, C. Morrison, E. Davies, J.M.C. Connell, Cortisol effects on body mass, blood pressure and cholesterol in the general population. Hypertension 33, 1364–1368 (1999)PubMedCrossRef
29.
go back to reference B.R. Walker, S. Soderberg, B. Lindhal, T. Ollsson, Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern. Med. 247, 198–204 (2000)PubMedCrossRef B.R. Walker, S. Soderberg, B. Lindhal, T. Ollsson, Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern. Med. 247, 198–204 (2000)PubMedCrossRef
30.
go back to reference Y. Imai, K. Abe, S. Sasaki, N. Minami, M. Nihei, M. Munakata, O. Murakami, K. Matsue, H. Sekino, Y. Miura, K. Yoshinaga, Altered circadian blood pressure rhythm in patients with Cushing’s syndrome. Hypertension 12, 11–19 (1988)PubMedCrossRef Y. Imai, K. Abe, S. Sasaki, N. Minami, M. Nihei, M. Munakata, O. Murakami, K. Matsue, H. Sekino, Y. Miura, K. Yoshinaga, Altered circadian blood pressure rhythm in patients with Cushing’s syndrome. Hypertension 12, 11–19 (1988)PubMedCrossRef
31.
go back to reference F. Fallo, P. Maffei, A. Dalla Pozza, M. Carli, P. Della Mea, M. Lupia, F. Rabbia, N. Sonino, Cardiovascular autonomic function in Cushing’s syndrome. J. Endocrinol. Invest. 32, 41–44 (2009)PubMed F. Fallo, P. Maffei, A. Dalla Pozza, M. Carli, P. Della Mea, M. Lupia, F. Rabbia, N. Sonino, Cardiovascular autonomic function in Cushing’s syndrome. J. Endocrinol. Invest. 32, 41–44 (2009)PubMed
32.
go back to reference T. Ohkubo, A. Hozawa, J. Yamaguchi, M. Kikuya, K. Ohmori, M. Michimata, M. Matsubara, J. Hashimoto, H. Hoshi, T. Araki, I. Tsuji, H. Satoh, S. Hisamichi, Y. Imai, Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20, 2183–2189 (2002)PubMedCrossRef T. Ohkubo, A. Hozawa, J. Yamaguchi, M. Kikuya, K. Ohmori, M. Michimata, M. Matsubara, J. Hashimoto, H. Hoshi, T. Araki, I. Tsuji, H. Satoh, S. Hisamichi, Y. Imai, Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20, 2183–2189 (2002)PubMedCrossRef
33.
go back to reference S. Schäfer, M. Kelm, S. Mingers, B.E. Strauer, Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J. Hypertens. 20, 1431–1437 (2002)PubMedCrossRef S. Schäfer, M. Kelm, S. Mingers, B.E. Strauer, Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J. Hypertens. 20, 1431–1437 (2002)PubMedCrossRef
34.
go back to reference L. Kornel, W.A. Nelson, B. Manisundaram, R. Chigurupati, T. Hayashi, Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 58, 580–587 (1993)PubMedCrossRef L. Kornel, W.A. Nelson, B. Manisundaram, R. Chigurupati, T. Hayashi, Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 58, 580–587 (1993)PubMedCrossRef
35.
go back to reference H. Inoue, K. Humesono, T. Nishimori, Y. Hirata, T. Tanabe, Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun. 254, 292–298 (1999)PubMedCrossRef H. Inoue, K. Humesono, T. Nishimori, Y. Hirata, T. Tanabe, Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun. 254, 292–298 (1999)PubMedCrossRef
36.
go back to reference I. Akaza, T. Yoshimoto, K. Tsuchiya, Y. Hirata, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome. Endocr. J. 57, 245–552 (2010)PubMedCrossRef I. Akaza, T. Yoshimoto, K. Tsuchiya, Y. Hirata, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome. Endocr. J. 57, 245–552 (2010)PubMedCrossRef
37.
go back to reference T.J. Anderson, A. Uehata, M.D. Gerhard, I.T. Meredith, S. Knab, D. Delagrange, E.H. Lieberman, P. Ganz, M.A. Creager, A.C. Yeung, A.P. Selwyn, Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235–1241 (1995)PubMedCrossRef T.J. Anderson, A. Uehata, M.D. Gerhard, I.T. Meredith, S. Knab, D. Delagrange, E.H. Lieberman, P. Ganz, M.A. Creager, A.C. Yeung, A.P. Selwyn, Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235–1241 (1995)PubMedCrossRef
38.
go back to reference J.A. Whitworth, G.J. Mangos, J.J. Kelly, Cushing, cortisol, and cardiovascular disease. Hypertension 36, 912–916 (2000)PubMedCrossRef J.A. Whitworth, G.J. Mangos, J.J. Kelly, Cushing, cortisol, and cardiovascular disease. Hypertension 36, 912–916 (2000)PubMedCrossRef
39.
go back to reference M. Rosenstock, S. Katz, A. Danon, Glucocorticoids regulate both phorbol ester and calcium ionophore-induced endothelial prostacyclin synthesis. Prostag. Leukotr. Ess. Fatty Acids 56, 1–8 (1997)CrossRef M. Rosenstock, S. Katz, A. Danon, Glucocorticoids regulate both phorbol ester and calcium ionophore-induced endothelial prostacyclin synthesis. Prostag. Leukotr. Ess. Fatty Acids 56, 1–8 (1997)CrossRef
40.
go back to reference S.S. Jun, Z. Chen, M.C. Pace, P.W. Shaul, Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium. Circ. Res. 84, 193–200 (1999)PubMedCrossRef S.S. Jun, Z. Chen, M.C. Pace, P.W. Shaul, Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium. Circ. Res. 84, 193–200 (1999)PubMedCrossRef
41.
go back to reference K.M. Rogers, C.A. Bonar, J.L. Estrella, S. Yang, Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am. J. Physiol. Heart Circ. Physiol. 283, H1922–H1928 (2002)PubMed K.M. Rogers, C.A. Bonar, J.L. Estrella, S. Yang, Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am. J. Physiol. Heart Circ. Physiol. 283, H1922–H1928 (2002)PubMed
42.
go back to reference S.L. Ong, J.A. Whitworth, How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol. Metab. Clin. North Am. 40, 393–407 (2011)PubMedCrossRef S.L. Ong, J.A. Whitworth, How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol. Metab. Clin. North Am. 40, 393–407 (2011)PubMedCrossRef
Metadata
Title
Coronary microvascular function in patients with Cushing’s syndrome
Authors
Francesco Fallo
Giulia Famoso
Dario Capizzi
Nicoletta Sonino
Francesca Dassie
Pietro Maffei
Chiara Martini
Agostino Paoletta
Sabino Iliceto
Francesco Tona
Publication date
01-02-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9764-2

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.